SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Yul Brynner Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientYul Brynner
Date of birth1920-07-11
IdentifiersMRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572
Document date2026-11-01
AuthorSimon Achterberg, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT. Concerns: His voice has become weak and breathy, and he cannot sing or project on stage; He wants to get back to performing and to keep working for as long as he can; He wants people to know what smoking did to him. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeksEvery 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panelIntravenous route1983-09-22activeS
Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastasesEvery 12 weeks, after calcium and creatinine, with a dental examination done firstIntravenous route1983-10-13activeS
Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acidOne tablet by mouth dailyOral route1983-10-13activeS
Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds)Apply a thin layer twice daily for up to two weeksTopical route1983-10-20activeS
Cetirizine 10 mg oral tablet, one tablet daily as needed for itchingOne tablet by mouth daily as needed for itchingOral route1983-10-20activeS

Procedures

ProcedureDatesStatusEvidence
Flexible laryngoscopy by the ENT surgeon: left vocal fold immobile in the paramedian position with incomplete glottic closure; no laryngeal mass or mucosal lesion1983-09-01 to 1983-09-01completedS
CT of the chest, abdomen, and pelvis with contrast: 5.2 cm left upper lobe mass invading the mediastinal fat of the aortopulmonary window and abutting the aortic arch and left pulmonary artery; enlarged aortopulmonary window (2.4 cm) and subcarinal (1.8 cm) lymph nodes; a small lytic lesion in the T10 vertebral body; no adrenal or liver lesion1983-09-01 to 1983-09-01completedS
FDG PET-CT: avid left upper lobe mass (SUVmax 14) with mediastinal invasion; avid aortopulmonary window and subcarinal nodes (N2); no contralateral or supraclavicular nodes; avid lytic lesions at T10, the right ilium, and the left sixth rib, without fracture (M1c)1983-09-04 to 1983-09-04completedS
MRI of the brain with contrast: no metastases1983-09-04 to 1983-09-04completedS
Endobronchial ultrasound-guided needle aspiration of subcarinal (station 7) and left lower paratracheal (4L) nodes: adenocarcinoma, TTF-1 and napsin A positive; PD-L1 (22C3) tumor proportion score 70 percent; tissue sent for comprehensive next-generation sequencing (reported 12 days later: KRAS G12V and TP53 mutations; no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration), with concordant plasma cell-free DNA testing1983-09-09 to 1983-09-09completedS
Outpatient palliative care visit: symptom assessment, coping, goals of care, and a plan for breathlessness and cough1983-09-29 to 1983-09-29completedS
Office injection medialization of the left vocal fold under laryngoscopic guidance by the ENT surgeon, to improve glottic closure and voice1983-10-06 to 1983-10-06completedS
Advance care planning conversation, about 30 minutes1983-10-27 to 1983-10-27completedS

Immunizations

DateVaccineStatusEvidence
1982-10-21Influenza vaccine, 1982-1983 seasoncompletedS
1977-03-17Tdap vaccinecompletedS
1983-10-27Influenza vaccine, 1983-1984 seasoncompletedS
1983-10-27Pneumococcal conjugate vaccine PCV20, single dosecompletedS
1983-10-27Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1971Heavy cigarette smoking for decades, quit twelve years before the index visitD (CLM-0004)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
His voice has become weak and breathy, and he cannot sing or project on stageactiveS
He wants to get back to performing and to keep working for as long as he canactiveS
He wants people to know what smoking did to himactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13.5 on 1983-10-13; Leukocytes [#/volume] in Blood by Automated count 7.2 on 1983-10-13; Platelets [#/volume] in Blood by Automated count 270 on 1983-10-13; Sodium [Moles/volume] in Serum or Plasma 138 on 1983-09-01; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1983-09-01; Creatinine [Mass/volume] in Serum or Plasma 0.9 on 1983-10-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M 92 on 1983-10-13; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1983-10-13; Albumin [Mass/volume] in Serum or Plasma 4 on 1983-09-01; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 on 1983-10-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 25 on 1983-10-20; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 101 on 1983-09-22; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 1983-10-20; Glucose [Mass/volume] in Serum or Plasma 104 on 1983-10-13; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 1983-10-13; Total score [Edmonton Symptom Assessment System] 12 on 1983-10-13; Thyrotropin [Units/volume] in Serum or Plasma 2.6 on 1983-10-20; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 on 1983-10-20; Cortisol [Mass/volume] in Serum or Plasma 14.2 on 1983-09-22; Eosinophils [#/volume] in Blood by Automated count 0.62 on 1983-10-20; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1983-10-27; Total score [AUDIT-C] 2 on 1983-10-27 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notesactiveconfirmed C34.12S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983.
Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer.
Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary windowactiveconfirmed J38.01S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor.
Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosisactiveconfirmed R91.8S — Synthetic presenting imaging finding, recorded before the tissue diagnosis.
Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco sinceactiveconfirmed Z87.891S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts.
Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement)activeconfirmed L27.0S — Synthetic common immune-related adverse event on checkpoint inhibitor therapy.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1983-09-01Hemoglobin [Mass/volume] in Blood13.8g/dL13.5-17.5 g/dLNormalS
1983-09-01Leukocytes [#/volume] in Blood by Automated count7.910*3/uL4-11 10*3/uLNormalS
1983-09-01Platelets [#/volume] in Blood by Automated count29010*3/uL150-400 10*3/uLNormalS
1983-09-01Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1983-09-01Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1983-09-01Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.7-1.3 mg/dLNormalS
1983-09-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M92mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1983-09-01Calcium [Mass/volume] in Serum or Plasma9.6mg/dL8.6-10.3 mg/dLNormalS
1983-09-01Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
1983-09-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
1983-09-01Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
1983-09-01Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma98U/L40-129 U/LNormalS
1983-09-01Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1983-09-01Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1983-09-01Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1983-09-15Total score [Edmonton Symptom Assessment System]18{score}S
1983-09-22Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.4-4 mIU/LNormalS
1983-09-22Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
1983-09-22Cortisol [Mass/volume] in Serum or Plasma14.2ug/dLMorning (8 a.m.) reference intervalNormalS
1983-09-22Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-55 U/LNormalS
1983-09-22Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L8-48 U/LNormalS
1983-09-22Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma101U/L40-129 U/LNormalS
1983-09-22Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1983-09-22Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.7-1.3 mg/dLNormalS
1983-09-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M92mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1983-09-22Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1983-09-22Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
1983-09-22Hemoglobin [Mass/volume] in Blood13.6g/dL13.5-17.5 g/dLNormalS
1983-09-22Leukocytes [#/volume] in Blood by Automated count7.610*3/uL4-11 10*3/uLNormalS
1983-09-22Platelets [#/volume] in Blood by Automated count28410*3/uL150-400 10*3/uLNormalS
1983-10-13Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.4-4 mIU/LNormalS
1983-10-13Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1983-10-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-55 U/LNormalS
1983-10-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-48 U/LNormalS
1983-10-13Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
1983-10-13Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.7-1.3 mg/dLNormalS
1983-10-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M92mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1983-10-13Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
1983-10-13Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1983-10-13Hemoglobin [Mass/volume] in Blood13.5g/dL13.5-17.5 g/dLNormalS
1983-10-13Leukocytes [#/volume] in Blood by Automated count7.210*3/uL4-11 10*3/uLNormalS
1983-10-13Platelets [#/volume] in Blood by Automated count27010*3/uL150-400 10*3/uLNormalS
1983-10-13Total score [Edmonton Symptom Assessment System]12{score}S
1983-10-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1983-10-20Thyrotropin [Units/volume] in Serum or Plasma2.6m[IU]/L0.4-4 mIU/LNormalS
1983-10-20Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1983-10-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
1983-10-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L8-48 U/LNormalS
1983-10-20Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1983-10-20Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.7-1.3 mg/dLNormalS
1983-10-20Eosinophils [#/volume] in Blood by Automated count0.6210*3/uL0-0.5 10*3/uLHighS
1983-10-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1983-10-27Total score [AUDIT-C]2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1983-09-01Body height178cmS
1983-09-01Body weight72.4kgS
1983-09-01Body mass index (BMI) [Ratio]22.9kg/m2S
1983-09-01Systolic blood pressure132mm[Hg]S
1983-09-01Diastolic blood pressure80mm[Hg]S
1983-09-01Heart rate82/minS
1983-09-01Respiratory rate16/minS
1983-09-01Body temperature36.8CelS
1983-09-01Oxygen saturation in Arterial blood by Pulse oximetry96%S
1983-09-15Body height178cmS
1983-09-15Body weight72kgS
1983-09-15Body mass index (BMI) [Ratio]22.7kg/m2S
1983-09-15Systolic blood pressure128mm[Hg]S
1983-09-15Diastolic blood pressure78mm[Hg]S
1983-09-15Heart rate80/minS
1983-09-15Respiratory rate16/minS
1983-09-15Body temperature36.7CelS
1983-09-15Oxygen saturation in Arterial blood by Pulse oximetry96%S
1983-09-22Body height178cmS
1983-09-22Body weight71.8kgS
1983-09-22Body mass index (BMI) [Ratio]22.7kg/m2S
1983-09-22Systolic blood pressure126mm[Hg]S
1983-09-22Diastolic blood pressure78mm[Hg]S
1983-09-22Heart rate78/minS
1983-09-22Respiratory rate16/minS
1983-09-22Body temperature36.6CelS
1983-09-22Oxygen saturation in Arterial blood by Pulse oximetry96%S
1983-10-13Body height178cmS
1983-10-13Body weight72.2kgS
1983-10-13Body mass index (BMI) [Ratio]22.8kg/m2S
1983-10-13Systolic blood pressure124mm[Hg]S
1983-10-13Diastolic blood pressure76mm[Hg]S
1983-10-13Heart rate76/minS
1983-10-13Respiratory rate16/minS
1983-10-13Body temperature36.7CelS
1983-10-13Oxygen saturation in Arterial blood by Pulse oximetry97%S
1983-10-20Body height178cmS
1983-10-20Body weight72kgS
1983-10-20Body mass index (BMI) [Ratio]22.7kg/m2S
1983-10-20Systolic blood pressure126mm[Hg]S
1983-10-20Diastolic blood pressure78mm[Hg]S
1983-10-20Heart rate78/minS
1983-10-20Respiratory rate16/minS
1983-10-20Body temperature36.7CelS
1983-10-20Oxygen saturation in Arterial blood by Pulse oximetry97%S
1983-10-27Body height178cmS
1983-10-27Body weight72.3kgS
1983-10-27Body mass index (BMI) [Ratio]22.8kg/m2S
1983-10-27Systolic blood pressure124mm[Hg]S
1983-10-27Diastolic blood pressure76mm[Hg]S
1983-10-27Heart rate74/minS
1983-10-27Respiratory rate16/minS
1983-10-27Body temperature36.6CelS
1983-10-27Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
1983-09-01New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CTfinishedS
1983-09-15Diagnosis and staging review with thoracic oncology consultationfinishedS
1983-09-22Biomarker results and start of first-line pembrolizumabfinishedS
1983-10-13Cycle 2 review: immune-related adverse event monitoring, symptoms, and return to workfinishedS
1983-10-20Same-day sick visit for an itchy rash on pembrolizumabfinishedS
1983-10-27Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoringcompletedGL-CMID-2026, GL-NCCN-NSCLC-2026S
Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallelcompletedGL-CMID-2026, GL-NCCN-NSCLC-2026S
First-line systemic therapy chosen by biomarkers once sequencing excludes an actionable alteration: pembrolizumab 200 mg every 3 weeks for PD-L1 50 percent or more, with response CT every 6 to 12 weeks; switch to 400 mg every 6 weeks to fit the tour once stablecompletedGL-CMID-2026, GL-NCCN-NSCLC-2026S
Immune-related adverse event monitoring: TSH and free T4, liver tests, creatinine, glucose, and blood count before each infusion; morning cortisol at baseline and for symptoms; written list of warning symptoms (diarrhea, cough or breathlessness, rash, yellowing, severe fatigue or headache) with a 24-hour oncology telephone linecompletedGL-ASCO-IRAE-2021, GL-CMID-2026S
Early integrated palliative care alongside cancer treatment, starting within eight weeks of diagnosis, with symptom (ESAS) and distress screening at each visit and advance care planningcompletedGL-ASCO-PALL-2017, GL-NCCN-DISTRESS-2026, GL-CMID-2026S
If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracturecompletedGL-CMID-2026, GL-NCCN-NSCLC-2026S
Voice and work: injection medialization of the left vocal fold, voice therapy with a speech-language pathologist, infusions scheduled on his day off, and a graded return to rehearsal and performance as he choosescompletedGL-CMID-2026, GL-NCCN-NSCLC-2026S
Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care teamcompletedGL-CMID-2026, GL-NCCN-NSCLC-2026S

Goals

GoalTargetStatusOutcomeProvenance
Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation1983-09-22completedDiagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewedS
First palliative care visit within eight weeks of diagnosis1983-10-13completedSeen by the palliative care team two weeks after diagnosisS
A voice strong enough for rehearsal by the second cycle1983-10-13completedLouder, less breathy voice one week after injection medialization; light rehearsal resumed with voice therapyS
No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit1983-10-13completedPanels normal before cycles 1 and 2; no symptoms of colitis, pneumonitis, hepatitis, or endocrine dysfunctionS
Zoledronic acid started only after a dental examination and normal calcium and kidney function1983-10-13completedDental examination three weeks earlier; calcium 9.4 and eGFR 92; first dose with cycle 2S

Functional Status

Mental Status